 5. In the absence of rapidly progressing disease, the interval from prior treatment to time of study drug administration should be 2 weeks for cytotoxic agents or at least 5 half-lives for noncytotoxic agents. Persistent clinically significant toxicities from prior chemotherapy or radiotherapy must not be greater than Grade 1. 